Ultrapotent human antibodies protect against SARS-CoV-2 challenge via multiple mechanisms

UCSF Chimera—A visualization system for exploratory research and analysis

Pettersen, E. F., Goddard, T. D., Huang, C. C., Couch, G. S., Greenblatt, D. M., Meng, E. C., & Ferrin, T. E. (2004) · Journal of Computational Chemistry · doi:10.1002/jcc.20084 · Cited by 45,260 · see citing works

A novel coronavirus from patients with pneumonia in China, 2019

Zhu, N., Zhang, D., Wang, W., Li, X., Yang, B., Song, J., Zhao, X., Huang, B., Shi, W., Lu, R., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2001017 · Cited by 28,244 · see citing works

Features and development of Coot

Emsley, P., Lohkamp, B., Scott, W. G., & Cowtan, K. D. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444910007493 · Cited by 27,510 · see citing works

A pneumonia outbreak associated with a new coronavirus of probable bat origin

Zhou, P., Yang, X.-L., Wang, X.-G., Hu, B., Zhang, L., Zhang, W., Si, H.-R., Zhu, Y., Li, B., Huang, C.-L., et al. (2020) · Nature · doi:10.1038/s41586-020-2012-7 · Cited by 21,969 · see citing works

<i>Phaser</i> crystallographic software

McCoy, A. J., Grosse-Kunstleve, R. W., Adams, P. D., Winn, M. D., Storoni, L. C., & Read, R. J. (2007) · Journal of Applied Crystallography · doi:10.1107/s0021889807021206 · Cited by 20,612 · see citing works

A SIMPLE METHOD OF ESTIMATING FIFTY PER CENT ENDPOINTS12

REED, L. J., & Muench, H. (1938) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a118408 · Cited by 20,341 · see citing works

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

Hoffmann, M., Kleine-Weber, H., Schroeder, S., Krüger, N., Herrler, T., Erichsen, S., Schiergens, T. S., Herrler, G., Wu, N.-H., Nitsche, A., et al. (2020) · Cell · doi:10.1016/j.cell.2020.02.052 · Cited by 20,286 · see citing works

<i>XDS</i>

Kabsch, W. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444909047337 · Cited by 16,463 · see citing works

<i>MolProbity</i> : all-atom structure validation for macromolecular crystallography

Chen, V. B., Arendall, W. B., Headd, J. J., Keedy, D. A., Immormino, R. M., Kapral, G. J., Murray, L. W., Richardson, J. S., & Richardson, D. C. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444909042073 · Cited by 14,115 · see citing works

cryoSPARC: algorithms for rapid unsupervised cryo-EM structure determination

Punjani, A., Rubinstein, J. L., Fleet, D. J., & Brubaker, M. A. (2017) · Nature Methods · doi:10.1038/nmeth.4169 · Cited by 9,168 · see citing works

Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation

Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897 · see citing works

Structure, function and antigenicity of the SARS-CoV-2 spike glycoprotein

Walls, A. C., Park, Y.-J., Tortorici, M. A., Wall, A., McGuire, A. T., & Veesler, D. (2020) · doi:10.1101/2020.02.19.956581 · Cited by 8,586 · see citing works

REFMAC 5 for the refinement of macromolecular crystal structures

Murshudov, G. N., Skubák, P., Lebedev, A. A., Pannu, N. S., Steiner, R. A., Nicholls, R. A., Winn, M., Long, F., & Vagin, A. A. (2011) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444911001314 · Cited by 8,385 · see citing works

Macromolecular structure determination using X-rays, neutrons and electrons: recent developments in Phenix

Liebschner, D. C., Afonine, P. V., Baker, M. L., Bunkòczi, G., Chen, V. B., Croll, T. I., Hintze, B. J., Hung, L., Jain, S., McCoy, A. J., et al. (2019) · Acta Crystallographica Section D Structural Biology · doi:10.1107/s2059798319011471 · Cited by 6,709 · see citing works

Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor

Lan, J., Ge, J., Yu, J., Shan, S., Zhou, H., Fan, S., Zhang, Q., Shi, X., Wang, Q., Zhang, L., et al. (2020) · Nature · doi:10.1038/s41586-020-2180-5 · Cited by 5,983 · see citing works

UCSF ChimeraX: Meeting modern challenges in visualization and analysis

Goddard, T. D., Huang, C. C., Meng, E. C., Pettersen, E. F., Couch, G. S., Morris, J. H., & Ferrin, T. E. (2018) · Protein Science · doi:10.1002/pro.3235 · Cited by 5,267 · see citing works

Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2

Yan, R., Zhang, Y., Li, Y., Xia, L., Guo, Y., & Zhou, Q. (2020) · Science · doi:10.1126/science.abb2762 · Cited by 4,950 · see citing works

Identification of a novel coronavirus in patients with severe acute respiratory syndrome

Drosten, C., Günther, S., Preiser, W., van der Werf, S., Brodt, H.-R., Becker, S., Rabenau, H., Panning, M., Kolesnikova, L., Fouchier, R. A. M., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030747 · Cited by 4,574 · see citing works

New tools for automated high-resolution cryo-EM structure determination in RELION-3

Zivanov, J., Nakane, T., Forsberg, B., Kimanius, D., Hagen, W., Lindahl, E., & Scheres, S. (2018) · eLife · doi:10.7554/elife.42166 · Cited by 4,377 · see citing works

A Novel Coronavirus Associated with Severe Acute Respiratory Syndrome

Tg, K., Erdman, D. D., Cs, G., Zaki, Peret, T. C. T., Emery, S. L., Tong, S., Urbani, C., Comer, J. A., Lim, W., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030781 · Cited by 4,345 · see citing works

Structural basis of receptor recognition by SARS-CoV-2

Shang, J., Ye, G., Shi, K., Wan, Y., Luo, C., Aihara, H., Geng, Q., Auerbach, A., & Li, F. (2020) · Nature · doi:10.1038/s41586-020-2179-y · Cited by 3,661 · see citing works

An mRNA Vaccine against SARS-CoV-2 — Preliminary Report

Jackson, L. A., Anderson, E. J., Rouphael, N. G., Roberts, P. C., Makhene, M., Coler, R. N., McCullough, M. P., Chappell, J. D., Denison, M. R., Stevens, L. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022483 · Cited by 3,237 · see citing works

Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses

Letko, M., Marzi, A., & Munster, V. (2020) · Nature Microbiology · doi:10.1038/s41564-020-0688-y · Cited by 3,109 · see citing works

Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV

Ou, X., Liu, Y., Lei, X., Li, P., Mi, D., Ren, L., Guo, L., Guo, R., Chen, T., Hu, J., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-15562-9 · Cited by 3,097 · see citing works

Structural and Functional Basis of SARS-CoV-2 Entry by Using Human ACE2

Wang, Q., Zhang, Y., Wu, L., Niu, S., Song, C., Zhang, Z., Lu, G., Qiao, C., Hu, Y., Yuen, K.-Y., et al. (2020) · Cell · doi:10.1016/j.cell.2020.03.045 · Cited by 2,892 · see citing works

Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial

Folegatti, P. M., Ewer, K. J., Aley, P. K., Angus, B., Becker, S., Belij-Rammerstorfer, S., Bellamy, D., Bibi, S., Bittaye, M., Clutterbuck, E. A., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31604-4 · Cited by 2,419 · see citing works

Deep Mutational Scanning of SARS-CoV-2 Receptor Binding Domain Reveals Constraints on Folding and ACE2 Binding

Starr, T. N., Greaney, A. J., Hilton, S. K., Ellis, D., Crawford, K. H. D., Dingens, A. S., Navarro, M. J., Bowen, J. E., Tortorici, M. A., Walls, A. C., et al. (2020) · Cell · doi:10.1016/j.cell.2020.08.012 · Cited by 1,956 · see citing works

Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody

Pinto, D., Park, Y.-J., Beltramello, M., Walls, A. C., Tortorici, M. A., Bianchi, S., Jaconi, S., Culap, K., Zatta, F., De Marco, A., et al. (2020) · Nature · doi:10.1038/s41586-020-2349-y · Cited by 1,885 · see citing works

Convergent Antibody Responses to SARS-CoV-2 in Convalescent Individuals

Robbiani, D. F., Gaebler, C., Muecksch, F., Lorenzi, J. C. C., Wang, Z., Cho, A., Agudelo, M., Barnes, C. O., Gazumyan, A., Finkin, S., et al. (2020) · Nature · doi:10.1038/s41586-020-2456-9 · Cited by 1,853 · see citing works

Automated molecular microscopy: The new Leginon system

Suloway, C. J. M., Pulokas, J., Fellmann, D., Cheng, A., Guerra, F., Quispe, J. D., Stagg, S. M., Potter, C. S., & Carragher, B. O. (2005) · Journal of Structural Biology · doi:10.1016/j.jsb.2005.03.010 · Cited by 1,681 · see citing works

Human neutralizing antibodies elicited by SARS-CoV-2 infection

Ju, B., Zhang, Q., Ge, J., Wang, R., Sun, J., Ge, X., Yu, J., Shan, S., Zhou, B., Song, S., et al. (2020) · Nature · doi:10.1038/s41586-020-2380-z · Cited by 1,667 · see citing works

SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies

Barnes, C. O., Jette, C. A., Abernathy, M. E., Dam, K.-M. A., Esswein, S. R., Gristick, H. B., Malyutin, A. G., Sharaf, N. G., Huey-Tubman, K. E., Lee, Y. E., et al. (2020) · Nature · doi:10.1038/s41586-020-2852-1 · Cited by 1,599 · see citing works

Non-uniform refinement: adaptive regularization improves single-particle cryo-EM reconstructionPreprint

Punjani, A., Zhang, H.-W., & Fleet, D. J. (2019) · Nature Methods · doi:10.1101/2019.12.15.877092 · Cited by 1,580 · see citing works

Phase 1/2 Study to Describe the Safety and Immunogenicity of a COVID-19 RNA Vaccine Candidate (BNT162b1) in Adults 18 to 55 Years of Age: Interim Report

Mulligan, M. J., Lyke, K. E., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Raabe, V., Bailey, R., Swanson, K. A., et al. (2020) · doi:10.1101/2020.06.30.20142570 · Cited by 1,569 · see citing works

Non-uniform refinement: adaptive regularization improves single-particle cryo-EM reconstruction

Punjani, A., Zhang, H., & Fleet, D. J. (2020) · Nature Methods · doi:10.1038/s41592-020-00990-8 · Cited by 1,559 · see citing works

The Impact of Mutations in SARS-CoV-2 Spike on Viral Infectivity and Antigenicity

Li, Q., Wu, J., Nie, J., Zhang, L., Hao, H., Liu, S., Zhao, C., Zhang, Q., Liu, H., Nie, L., et al. (2020) · Cell · doi:10.1016/j.cell.2020.07.012 · Cited by 1,420 · see citing works

Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology

Piccoli, L., Park, Y.-J., Tortorici, M. A., Czudnochowski, N., Walls, A. C., Beltramello, M., Silacci-Fregni, C., Pinto, D., Rosen, L. E., Bowen, J. E., et al. (2020) · Cell · doi:10.1016/j.cell.2020.09.037 · Cited by 1,395 · see citing works

Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial

Zhu, F.-C., Li, Y.-H., Guan, X.-H., Hou, L.-H., Wang, W.-J., Li, J.-X., Wu, S.-P., Wang, B.-S., Wang, Z., Wang, L., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31208-3 · Cited by 1,382 · see citing works

Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike

Liu, L., Wang, P., Nair, M. S., Yu, J., Rapp, M., Wang, Q., Luo, Y., Chan, J. F.-W., Sahi, V., Figueroa, A., et al. (2020) · Nature · doi:10.1038/s41586-020-2571-7 · Cited by 1,349 · see citing works

Structure-based design of prefusion-stabilized SARS-CoV-2 spikes

Hsieh, C.-L., Goldsmith, J. A., Schaub, J. M., DiVenere, A. M., Kuo, H.-C., Javanmardi, K., Le, K. C., Wrapp, D., Lee, A. G., Liu, Y., et al. (2020) · Science · doi:10.1126/science.abd0826 · Cited by 1,303 · see citing works

A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2

Shi, R., Shan, C., Duan, X., Chen, Z., Liu, P., Song, J., Song, T., Bi, X., Han, C., Wu, L., et al. (2020) · Nature · doi:10.1038/s41586-020-2381-y · Cited by 1,286 · see citing works

Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model

Rogers, T. F., Zhao, F., Huang, D., Beutler, N., Burns, A., He, W.-T., Limbo, O., Smith, C., Song, G., Woehl, J., et al. (2020) · Science · doi:10.1126/science.abc7520 · Cited by 1,230 · see citing works

IMGT/V-QUEST: the highly customized and integrated system for IG and TR standardized V-J and V-D-J sequence analysis

Brochet, X., Lefranc, M., & Giudicelli, V. (2008) · Nucleic Acids Research · doi:10.1093/nar/gkn316 · Cited by 1,220 · see citing works

Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail

Hansen, J., Baum, A., Pascal, K. E., Russo, V., Giordano, S., Wloga, E., Fulton, B. O., Yan, Y., Koon, K., Patel, K., et al. (2020) · Science · doi:10.1126/science.abd0827 · Cited by 1,210 · see citing works

Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability

Brouwer, P. J. M., Caniels, T. G., van der Straten, K., Snitselaar, J. L., Aldon, Y., Bangaru, S., Torres, J. L., Okba, N. M. A., Claireaux, M., Kerster, G., et al. (2020) · Science · doi:10.1126/science.abc5902 · Cited by 1,140 · see citing works

Structures and distributions of SARS-CoV-2 spike proteins on intact virions

Ke, Z., Otón, J., Qu, K., Cortese, M., Žíla, V., McKeane, L., Nakane, T., Zivanov, J., Neufeldt, C. J., Cerikan, B., et al. (2020) · Nature · doi:10.1038/s41586-020-2665-2 · Cited by 1,114 · see citing works

Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen

Pallesen, J., Wang, N., Corbett, K. S., Wrapp, D., Kirchdoerfer, R. N., Turner, H. L., Cottrell, C. A., Becker, M. M., Wang, L., Shi, W., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1707304114 · Cited by 1,073 · see citing works

Potently neutralizing and protective human antibodies against SARS-CoV-2

Zost, S. J., Gilchuk, P., Case, J. B., Binshtein, E., Chen, R. E., Nkolola, J. P., Schäfer, A., Reidy, J. X., Trivette, A., Nargi, R. S., et al. (2020) · Nature · doi:10.1038/s41586-020-2548-6 · Cited by 1,041 · see citing works

High-resolution noise substitution to measure overfitting and validate resolution in 3D structure determination by single particle electron cryomicroscopy

Chen, S., McMullan, G., Faruqi, A. R., Murshudov, G. N., Short, J. M., Scheres, S. H. W., & Henderson, R. A. (2013) · Ultramicroscopy · doi:10.1016/j.ultramic.2013.06.004 · Cited by 1,005 · see citing works

DNA vaccine protection against SARS-CoV-2 in rhesus macaques

Yu, J., Tostanoski, L. H., Peter, L., Mercado, N. B., McMahan, K., Mahrokhian, S. H., Nkolola, J. P., Liu, J., Li, Z., Chandrashekar, A., et al. (2020) · Science · doi:10.1126/science.abc6284 · Cited by 997 · see citing works

A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2

Wu, Y., Wang, F., Shen, C., Peng, W., Li, D., Zhao, C., Li, Z., Li, S., Bi, Y., Yang, Y., et al. (2020) · Science · doi:10.1126/science.abc2241 · Cited by 955 · see citing works

A Bayesian approach to beam-induced motion correction in cryo-EM single-particle analysis

Zivanov, J., Nakane, T., & Scheres, S. H. W. (2018) · IUCrJ · doi:10.1107/s205225251801463x · Cited by 947 · see citing works

Real-time cryo–EM data pre-processing with Warp

Tegunov, D., & Cramer, P. (2018) · Nature Methods · doi:10.1038/s41592-019-0580-y · Cited by 923 · see citing works

Accelerated cryo-EM structure determination with parallelisation using GPUs in RELION-2

Kimanius, D., Forsberg, B. O., Scheres, S. H. W., & Lindahl, E. R. (2016) · eLife · doi:10.7554/elife.18722 · Cited by 903 · see citing works

Structures of Human Antibodies Bound to SARS-CoV-2 Spike Reveal Common Epitopes and Recurrent Features of Antibodies

Barnes, C. O., West, A. P., Huey-Tubman, K. E., Hoffmann, M. A. G., Sharaf, N. G., Hoffman, P. R., Koranda, N., Gristick, H. B., Gaebler, C., Muecksch, F., et al. (2020) · Cell · doi:10.1016/j.cell.2020.06.025 · Cited by 795 · see citing works

Structural insights into coronavirus entry

(2019) · Advances in Virus Research · doi:10.1016/bs.aivir.2019.08.002 · Cited by 769 · see citing works

Unexpected Receptor Functional Mimicry Elucidates Activation of Coronavirus Fusion

Walls, A. C., Xiong, X., Park, Y.-J., Tortorici, M. A., Snijder, J., Quispe, J., Cameroni, E., Gopal, R., Dai, M., Lanzavecchia, A., et al. (2019) · Cell · doi:10.1016/j.cell.2018.12.028 · Cited by 582 · see citing works

A Novel Bat Coronavirus Closely Related to SARS-CoV-2 Contains Natural Insertions at the S1/S2 Cleavage Site of the Spike Protein

Zhou, H., Chen, X., Hu, T., Li, J., Song, H., Liu, Y., Wang, P., Liu, D., Yang, J., Holmes, E. C., et al. (2020) · Current Biology · doi:10.1016/j.cub.2020.05.023 · Cited by 562 · see citing works

A three-dimensional model to analyze drug-drug interactions

Prichard, M. N., & Shipman, C. (1990) · Antiviral Research · doi:10.1016/0166-3542(90)90001-n · Cited by 545 · see citing works

A new class of highly potent, broadly neutralizing antibodies isolated from viremic patients infected with dengue virus

Dejnirattisai, W., Wongwiwat, W., Supasa, S., Zhang, X., Dai, X., Rouvinski, A., Jumnainsong, A., Edwards, C., Quyen, N. T. H., Duangchinda, T., et al. (2014) · Nature Immunology · doi:10.1038/ni.3058 · Cited by 504 · see citing works

Stabilized coronavirus spikes are resistant to conformational changes induced by receptor recognition or proteolysis

Kirchdoerfer, R. N., Wang, N., Pallesen, J., Wrapp, D., Turner, H. L., Cottrell, C. A., Corbett, K. S., Graham, B. S., McLellan, J. S., & Ward, A. B. (2018) · Scientific Reports · doi:10.1038/s41598-018-34171-7 · Cited by 466 · see citing works

Automated structure refinement of macromolecular assemblies from cryo-EM maps using Rosetta

Wang, R. Y.-R., Song, Y., Barad, B. A., Cheng, Y., Fraser, J. S., & DiMaio, F. (2016) · eLife · doi:10.7554/elife.17219 · Cited by 457 · see citing works

An ultrapotent synthetic nanobody neutralizes SARS-CoV-2 by stabilizing inactive Spike

Schoof, M., Faust, B., Saunders, R. A., Sangwan, S., Rezelj, V. V., Hoppe, N., Boone, M., Billesbølle, C. B., Puchades, C., Azumaya, C. M., et al. (2020) · Science · doi:10.1126/science.abe3255 · Cited by 428 · see citing works

Neutralizing Antibody and Soluble ACE2 Inhibition of a Replication-Competent VSV-SARS-CoV-2 and a Clinical Isolate of SARS-CoV-2

Case, J. B., Rothlauf, P. W., Chen, R. E., Liu, Z., Zhao, H., Kim, A. S., Bloyet, L.-M., Zeng, Q., Tahan, S., Droit, L., et al. (2020) · Cell Host &amp; Microbe · doi:10.1016/j.chom.2020.06.021 · Cited by 410 · see citing works

Privateer: software for the conformational validation of carbohydrate structures

Agirre, J., Iglesias‐Fernández, J., Rovira, C., Davies, G. J., Wilson, K. S., & Cowtan, K. D. (2015) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.3115 · Cited by 373 · see citing works

Atomic-accuracy models from 4.5-Å cryo-electron microscopy data with density-guided iterative local refinement

DiMaio, F., Song, Y., Li, X., Brunner, M. J., Xu, C., Conticello, V. P., Egelman, E. H., Marlovits, T. C., Cheng, Y., & Baker, D. A. (2015) · Nature Methods · doi:10.1038/nmeth.3286 · Cited by 309 · see citing works

A human monoclonal antibody blocking SARS-CoV-2 infectionPreprint

Wang, C., Li, W., Drabek, D., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.03.11.987958 · Cited by 289 · see citing works

A nanoluciferase SARS-CoV-2 for rapid neutralization testing and screening of anti-infective drugs for COVID-19

Xie, X., Muruato, A. E., Zhang, X., Lokugamage, K. G., Fontes-Garfias, C. R., Zou, J., Liu, J., Ren, P., Balakrishnan, M., Cihlář, T., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-19055-7 · Cited by 216 · see citing works

A Potently Neutralizing Antibody Protects Mice against SARS-CoV-2 Infection

Alsoussi, W. B., Turner, J. S., Case, J. B., Zhao, H., Schmitz, A. J., Zhou, J. Q., Chen, R. E., Lei, T., Rizk, A. A., McIntire, K. M., et al. (2020) · The Journal of Immunology · doi:10.4049/jimmunol.2000583 · Cited by 181 · see citing works

Structure-guided covalent stabilization of coronavirus spike glycoprotein trimers in the closed conformation

McCallum, M., Walls, A. C., Bowen, J. E., Corti, D., & Veesler, D. (2020) · Nature Structural & Molecular Biology · doi:10.1038/s41594-020-0483-8 · Cited by 163 · see citing works

An Antibody Targeting the Fusion Machinery Neutralizes Dual-Tropic Infection and Defines a Site of Vulnerability on Epstein-Barr Virus

Snijder, J., Ortego, M. S., Weidle, C., Stuart, A. B., Gray, M. D., McElrath, M. J., Pancera, M., Veesler, D., & McGuire, A. T. (2018) · Immunity · doi:10.1016/j.immuni.2018.03.026 · Cited by 140 · see citing works

Vaccine-Elicited Tier 2 HIV-1 Neutralizing Antibodies Bind to Quaternary Epitopes Involving Glycan-Deficient Patches Proximal to the CD4 Binding Site

Crooks, E. T., Tong, T., Chakrabarti, B. K., Narayan, K. M., Georgiev, I. S., Menis, S., Huang, X., Kulp, D. W., Osawa, K., Muranaka, J., et al. (2015) · PLoS Pathogens · doi:10.1371/journal.ppat.1004932 · Cited by 138 · see citing works

The role and function of Fcγ receptors on myeloid cells

Bournazos, S., Wang, T. T., & Ravetch, J. V. (2016) · Microbiology Spectrum · doi:10.1128/microbiolspec.mchd-0045-2016 · Cited by 138 · see citing works

Neutralization of West Nile virus by cross-linking of its surface proteins with Fab fragments of the human monoclonal antibody CR4354

Kaufmann, B., Vogt, M. R., Goudsmit, J., Holdaway, H. A., Aksyuk, A. A., Chipman, P. R., Kuhn, R. J., Diamond, M., & Rossmann, M. G. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1011036107 · Cited by 126 · see citing works

Automatically Fixing Errors in Glycoprotein Structures with Rosetta

Frenz, B., Rämisch, S., Borst, A. J., Walls, A. C., Adolf‐Bryfogle, J., Schief, W. R., Veesler, D., & DiMaio, F. (2018) · Structure · doi:10.1016/j.str.2018.09.006 · Cited by 104 · see citing works

Publisher Correction: Stabilized coronavirus spikes are resistant to conformational changes induced by receptor recognition or proteolysis

Kirchdoerfer, R. N., Wang, N., Pallesen, J., Wrapp, D., Turner, H. L., Cottrell, C. A., Corbett, K. S., Graham, B. S., McLellan, J. S., & Ward, A. B. (2018) · Scientific Reports · doi:10.1038/s41598-018-36918-8 · Cited by 98 · see citing works

Concurrent human antibody and T H 1 type T-cell responses elicited by a COVID-19 RNA vaccinePreprint

Şahin, U., Muik, A., Derhovanessian, E., et al. (2020) · medRxiv · doi:10.1101/2020.07.17.20140533 · Cited by 67 · see citing works

Characterization of neutralizing antibodies from a SARS-CoV-2 infected individualPreprint

Seydoux, E., Homad, L. J., MacCamy, A. J., Parks, K. R., Hurlburt, N. K., Jennewein, M. F., Akins, N. R., Stuart, A. B., Wan, Y.-H., Feng, J., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.05.12.091298 · Cited by 64 · see citing works

The development of therapeutic antibodies against dengue virus

Fibriansah, G., & Lok, S. (2016) · Antiviral Research · doi:10.1016/j.antiviral.2016.01.002 · Cited by 62 · see citing works

Structural basis of a potent human monoclonal antibody against Zika virus targeting a quaternary epitope

Long, F., Doyle, M., Fernández, E., Miller, A. S., Klose, T., Sevvana, M., Bryan, A. L., Davidson, E., Doranz, B. J., Kuhn, R. J., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1815432116 · Cited by 59 · see citing works

STAT2 signaling as double-edged sword restricting viral dissemination but driving severe pneumonia in SARS-CoV-2 infected hamstersPreprint

Boudewijns, R., Thibaut, H. J., Kaptein, S. J. F., Li, R., Vergote, V., Seldeslachts, L., Keyzer, C. D., Bervoets, L., Sharma, S., Weyenbergh, J. V., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.04.23.056838 · Cited by 53 · see citing works

An ultra-potent synthetic nanobody neutralizes SARS-CoV-2 by locking Spike into an inactive conformationPreprint

Schoof, M., Faust, B., Saunders, R. A., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.08.08.238469 · Cited by 49 · see citing works

Human dengue virus serotype 2 neutralizing antibodies target two distinct quaternary epitopes

Gallichotte, E. N., Baric, T. J., Yount, B. L., Widman, D. G., Durbin, A. P., Whitehead, S., Baric, R. S., & de Silva, A. M. (2018) · PLoS Pathogens · doi:10.1371/journal.ppat.1006934 · Cited by 47 · see citing works

Cryo-EM Structures Delineate a pH-Dependent Switch that Mediates Endosomal Positioning of SARS-CoV-2 Spike Receptor-Binding DomainsPreprint

Zhou, T., Tsybovsky, Y., Olia, A. S., Gorman, J., Rapp, M., Cerutti, G., Chuang, G., Katsamba, P. S., Nazzari, A. F., Sampson, J. M., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.07.04.187989 · Cited by 46 · see citing works

Structural Basis of Pan-Ebolavirus Neutralization by a Human Antibody against a Conserved, yet Cryptic Epitope

West, B. R., Moyer, C. L., King, L., Fusco, M. L., Milligan, J. C., Hui, S., & Saphire, E. O. (2018) · mBio · doi:10.1128/mbio.01674-18 · Cited by 45 · see citing works

A nanoluciferase SARS-CoV-2 for rapid neutralization testing and screening of anti-infective drugs for COVID-19Preprint

Xie, X., Muruato, A. E., Zhang, X., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.06.22.165712 · Cited by 41 · see citing works

Structural classification of neutralizing antibodies against the SARS-CoV-2 spike receptor-binding domain suggests vaccine and therapeutic strategiesPreprint

Barnes, C. O., Jette, C. A., Abernathy, M. E., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.08.30.273920 · Cited by 38 · see citing works

Transplantation of a quaternary structure neutralizing antibody epitope from dengue virus serotype 3 into serotype 4

Widman, D. G., Young, E., Nivarthi, U. K., Swanstrom, J., Royal, S. R., Yount, B. L., Debbink, K. M., Begley, M., Marcet, S., Durbin, A. P., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-17355-5 · Cited by 22 · see citing works

Faculty Opinions recommendation of A human monoclonal antibody blocking SARS-CoV-2 infection.

Wang, Y. (2020) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.737868308.793574192 · Cited by 5 · see citing works

Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies

Cao, Y., Wang, J., Jian, F., Xiao, T., Song, W., Yisimayi, A., Huang, W., Li, Q., Wang, P., An, R., et al. (2022) · Nature · doi:10.1038/s41586-021-04385-3 · Cited by 2,006 · see citing works

Evolution of antibody immunity to SARS-CoV-2

Gaebler, C., Wang, Z., Lorenzi, J. C. C., Muecksch, F., Finkin, S., Tokuyama, M., Cho, A., Jankovic, M., Schaefer-Babajew, D., Oliveira, T. Y., et al. (2021) · Nature · doi:10.1038/s41586-021-03207-w · Cited by 1,674 · see citing works

mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants

Wang, Z., Schmidt, F., Weisblum, Y., Muecksch, F., Barnes, C. O., Finkin, S., Schaefer-Babajew, D., Cipolla, M., Gaebler, C., Lieberman, J. A., et al. (2021) · Nature · doi:10.1038/s41586-021-03324-6 · Cited by 1,343 · see citing works

Complete Mapping of Mutations to the SARS-CoV-2 Spike Receptor-Binding Domain that Escape Antibody Recognition

Greaney, A. J., Starr, T. N., Gilchuk, P., Zost, S. J., Binshtein, E., Loes, A. N., Hilton, S. K., Huddleston, J., Eguia, R., Crawford, K. H. D., et al. (2021) · Cell Host &amp; Microbe · doi:10.1016/j.chom.2020.11.007 · Cited by 1,016 · see citing works

Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift

Cameroni, E., Bowen, J. E., Rosen, L. E., Saliba, C., Zepeda, S. K., Culap, K., Pinto, D., VanBlargan, L. A., Marco, A. D., di Iulio, J., et al. (2021) · Nature · doi:10.1038/s41586-021-04386-2 · Cited by 1,043 · see citing works

N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2

McCallum, M., De Marco, A., Lempp, F. A., Tortorici, M. A., Pinto, D., Walls, A. C., Beltramello, M., Chen, A., Liu, Z., Zatta, F., et al. (2021) · Cell · doi:10.1016/j.cell.2021.03.028 · Cited by 901 · see citing works

Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies

Chen, R. E., Zhang, X., Case, J. B., Winkler, E. S., Liu, Y., VanBlargan, L. A., Liu, J., Errico, J. M., Xie, X., Suryadevara, N., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01294-w · Cited by 881 · see citing works

SARS-CoV-2 B.1.1.7 sensitivity to mRNA vaccine-elicited, convalescent and monoclonal antibodies

Collier, D. A., De Marco, A., Ferreira, I. A. T. M., Meng, B., Datir, R., Walls, A. C., Kemp S, S. A., Bassi, J., Pinto, D., Fregni, C. S., et al. (2021) · doi:10.1101/2021.01.19.21249840 · Cited by 729 · see citing works

Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies

Collier, D. A., De Marco, A., Ferreira, I. A. T. M., Meng, B., Datir, R. P., Walls, A. C., Kemp, S. A., Bassi, J., Pinto, D., Silacci-Fregni, C., et al. (2021) · Nature · doi:10.1038/s41586-021-03412-7 · Cited by 728 · see citing works

SARS-CoV-2 Omicron variant: Antibody evasion and cryo-EM structure of spike protein–ACE2 complex

Mannar, D., Saville, J. W., Zhu, X., Srivastava, S. S., Berezuk, A. M., Tuttle, K. S., Marquez, A. C., Sekirov, I., & Subramaniam, S. (2022) · Science · doi:10.1126/science.abn7760 · Cited by 630 · see citing works

An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies

VanBlargan, L. A., Errico, J. M., Halfmann, P., Zost, S. J., Crowe, J. E., Purcell, L. A., Kawaoka, Y., Corti, D., Fremont, D. H., & Diamond, M. (2022) · Nature Medicine · doi:10.1038/s41591-021-01678-y · Cited by 676 · see citing works

SARS-CoV-2 Omicron virus causes attenuated disease in mice and hamsters

Halfmann, P., Iida, S., Iwatsuki‐Horimoto, K., Maemura, T., Kiso, M., Scheaffer, S. M., Darling, T. L., Joshi, A., Loeber, S. J., Singh, G., et al. (2022) · Nature · doi:10.1038/s41586-022-04441-6 · Cited by 654 · see citing works

Circulating SARS-CoV-2 spike N439K variants maintain fitness while evading antibody-mediated immunity

Thomson, E. C., Rosen, L. E., Shepherd, J. G., Spreafico, R., da Silva Filipe, A., Wojcechowskyj, J. A., Davis, C., Piccoli, L., Pascall, D. J., Dillen, J., et al. (2021) · Cell · doi:10.1016/j.cell.2021.01.037 · Cited by 606 · see citing works

Elicitation of Potent Neutralizing Antibody Responses by Designed Protein Nanoparticle Vaccines for SARS-CoV-2

Walls, A. C., Fiala, B., Schäfer, A., Wrenn, S., Pham, M. N., Murphy, M., Tse, L. V., Shehata, L., O’Connor, M. A., Chen, C., et al. (2020) · Cell · doi:10.1016/j.cell.2020.10.043 · Cited by 532 · see citing works

Complete map of SARS-CoV-2 RBD mutations that escape the monoclonal antibody LY-CoV555 and its cocktail with LY-CoV016

Starr, T. N., Greaney, A. J., Dingens, A. S., & Bloom, J. D. (2021) · Cell Reports Medicine · doi:10.1016/j.xcrm.2021.100255 · Cited by 470 · see citing works

SARS-CoV-2 RBD antibodies that maximize breadth and resistance to escape

Starr, T. N., Czudnochowski, N., Liu, Z., Zatta, F., Park, Y., Addetia, A., Pinto, D., Beltramello, M., Hernandez, P., Greaney, A. J., et al. (2021) · Nature · doi:10.1038/s41586-021-03807-6 · Cited by 495 · see citing works

SARS-CoV-2 immune evasion by the B.1.427/B.1.429 variant of concern

McCallum, M., Bassi, J., De Marco, A., Chen, A., Walls, A. C., Di Iulio, J., Tortorici, M. A., Navarro, M.-J., Silacci-Fregni, C., Saliba, C., et al. (2021) · Science · doi:10.1126/science.abi7994 · Cited by 412 · see citing works

Spread of a SARS-CoV-2 variant through Europe in the summer of 2020

Hodcroft, E. B., Zuber, M., Nadeau, S., Vaughan, T. G., Crawford, K. H. D., Althaus, C. L., Reichmuth, M. L., Bowen, J. E., Walls, A. C., Corti, D., et al. (2021) · Nature · doi:10.1038/s41586-021-03677-y · Cited by 425 · see citing works

An ultrapotent synthetic nanobody neutralizes SARS-CoV-2 by stabilizing inactive Spike

Schoof, M., Faust, B., Saunders, R. A., Sangwan, S., Rezelj, V. V., Hoppe, N., Boone, M., Billesbølle, C. B., Puchades, C., Azumaya, C. M., et al. (2020) · Science · doi:10.1126/science.abe3255 · Cited by 428 · see citing works

Structure-guided multivalent nanobodies block SARS-CoV-2 infection and suppress mutational escape

Koenig, P., Das, H., Liu, H., Kümmerer, B., Gohr, F. N., Jenster, L.-M., Schiffelers, L. D. J., Tesfamariam, Y., Uchima, M., Wuerth, J. D., et al. (2021) · Science · doi:10.1126/science.abe6230 · Cited by 141 · see citing works

Broad betacoronavirus neutralization by a stem helix–specific human antibody

Pinto, D., Sauer, M. M., Czudnochowski, N., Low, J. S., Tortorici, M. A., Housley, M. P., Noack, J., Walls, A. C., Bowen, J. E., Guarino, B., et al. (2021) · Science · doi:10.1126/science.abj3321 · Cited by 381 · see citing works

Tackling COVID-19 with neutralizing monoclonal antibodies

Corti, D., Purcell, L. A., Snell, G., & Veesler, D. (2021) · Cell · doi:10.1016/j.cell.2021.05.005 · Cited by 375 · see citing works

Structural and functional ramifications of antigenic drift in recent SARS-CoV-2 variants

Yuan, M., Huang, D., Lee, C.-C. D., Wu, N. C., Jackson, A. M., Zhu, X., Liu, H., Peng, L., van Gils, M. J., Sanders, R. W., et al. (2021) · doi:10.1101/2021.02.16.430500 · Cited by 364 · see citing works

Distinguishing features of current COVID-19 vaccines: knowns and unknowns of antigen presentation and modes of action

Heinz, F., & Stiasny, K. (2021) · npj Vaccines · doi:10.1038/s41541-021-00369-6 · Cited by 329 · see citing works

SARS-CoV-2 variant evasion of monoclonal antibodies based on in vitro studies

Cox, M., Peacock, T. P., Harvey, W. T., Hughes, J., Wright, D. W., Willett, B. J., Thomson, E. C., Gupta, R. K., Peacock, S. J., Robertson, D. L., et al. (2022) · Nature Reviews Microbiology · doi:10.1038/s41579-022-00809-7 · Cited by 336 · see citing works

Emergence and spread of a SARS-CoV-2 variant through Europe in the summer of 2020Preprint

Hodcroft, E. B., Zuber, M., Nadeau, S., Vaughan, T. G., Crawford, K. H. D., Althaus, C. L., Reichmuth, M. L., Bowen, J. E., Walls, A. C., Corti, D., et al. (2020) · medRxiv · doi:10.1101/2020.10.25.20219063 · Cited by 326 · see citing works

Defining variant-resistant epitopes targeted by SARS-CoV-2 antibodies: A global consortium study

Hastie, K. M., Li, H., Bedinger, D., Schendel, S. L., Dennison, S. M., Li, K., Rayaprolu, V., Yu, X., Mann, C. J., Zandonatti, M. A., et al. (2021) · Science · doi:10.1126/science.abh2315 · Cited by 299 · see citing works

Lectins enhance SARS-CoV-2 infection and influence neutralizing antibodies

Lempp, F. A., Soriaga, L. B., Montiel-Ruiz, M., Benigni, F., Noack, J., Park, Y., Bianchi, S., Walls, A. C., Bowen, J. E., Zhou, J., et al. (2021) · Nature · doi:10.1038/s41586-021-03925-1 · Cited by 292 · see citing works

Genetic and structural basis for SARS-CoV-2 variant neutralization by a two-antibody cocktail

Dong, J., Zost, S. J., Greaney, A. J., Starr, T. N., Dingens, A. S., Chen, E. C., Chen, R. E., Case, J. B., Sutton, R. E., Gilchuk, P., et al. (2021) · Nature Microbiology · doi:10.1038/s41564-021-00972-2 · Cited by 285 · see citing works

Molecular basis of immune evasion by the Delta and Kappa SARS-CoV-2 variants

McCallum, M., Walls, A. C., Sprouse, K. R., Bowen, J. E., Rosen, L. E., Dang, H. V., Marco, A. D., Franko, N., Tilles, S. W., Logue, J. K., et al. (2021) · Science · doi:10.1126/science.abl8506 · Cited by 273 · see citing works

Antibodies to combat viral infections: development strategies and progress

Pantaleo, G., Correia, B. E., Fenwick, C. W., Joo, V., & Perez, L. H. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00495-3 · Cited by 286 · see citing works

Insights to SARS-CoV-2 life cycle, pathophysiology, and rationalized treatments that target COVID-19 clinical complications

Trougakos, I. P., Stamatelopoulos, K. S., Terpos, E., Tsitsilonis, O., Aivalioti, E., Paraskevis, D. N., Kastritis, E., Pavlakis, G. N., & Dimopoulos, M. A. (2021) · Journal of Biomedical Science · doi:10.1186/s12929-020-00703-5 · Cited by 284 · see citing works

Affinity maturation of SARS-CoV-2 neutralizing antibodies confers potency, breadth, and resilience to viral escape mutations

Muecksch, F., Weisblum, Y., Barnes, C., Schmidt, F., Schaefer-Babajew, D. J., Wang, Z.-J., Lorenzi, J. C. C., Flyak, A., DeLaitsch, A. T., Huey-Tubman, K. E., et al. (2021) · Immunity · doi:10.1016/j.immuni.2021.07.008 · Cited by 256 · see citing works

Monoclonal antibody therapies against SARS-CoV-2

Focosi, D., McConnell, S. A., Casadevall, A., Cappello, E., Valdiserra, G., & Tuccori, M. (2022) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(22)00311-5 · Cited by 262 · see citing works

Broad sarbecovirus neutralization by a human monoclonal antibody

Tortorici, M. A., Czudnochowski, N., Starr, T. N., Marzi, R., Walls, A. C., Zatta, F., Bowen, J. E., Jaconi, S., di Iulio, J., Wang, Z., et al. (2021) · Nature · doi:10.1038/s41586-021-03817-4 · Cited by 251 · see citing works

Prevalent, protective, and convergent IgG recognition of SARS-CoV-2 non-RBD spike epitopes

Voss, W. N., Hou, Y. J., Johnson, N. V., Delidakis, G., Kim, J. E., Javanmardi, K., Horton, A. P., Bartzoka, F., Paresi, C., Tanno, Y., et al. (2021) · Science · doi:10.1126/science.abg5268 · Cited by 248 · see citing works

mRNA Vaccines in the COVID-19 Pandemic and Beyond

Hogan, M. J., & Pardi, N. (2021) · Annual Review of Medicine · doi:10.1146/annurev-med-042420-112725 · Cited by 252 · see citing works

Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift

Cameroni, E., Bowen, J. E., Rosen, L. E., Saliba, C., Zepeda, S. K., Culap, K., Pinto, D., VanBlargan, L. A., Marco, A. D., di Iulio, J., et al. (2021) · Nature · doi:10.1038/d41586-021-03825-4 · Cited by 247 · see citing works

Imprinted antibody responses against SARS-CoV-2 Omicron sublineages

Park, Y., Pinto, D., Walls, A. C., Liu, Z., Marco, A. D., Benigni, F., Zatta, F., Silacci-Fregni, C., Bassi, J., Sprouse, K. R., et al. (2022) · Science · doi:10.1126/science.adc9127 · Cited by 225 · see citing works

Monoclonal antibodies for COVID-19 therapy and SARS-CoV-2 detection

Hwang, Y.-C., Lu, R.-M., Su, S.-C., Chiang, P.-Y., Ko, S.-H., Ke, F.-Y., Liang, K., Hsieh, T.-Y., & Wu, H.-C. (2022) · Journal of Biomedical Sciences · doi:10.1186/s12929-021-00784-w · Cited by 202 · see citing works

Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies

Cao, Y., Wang, J., Jian, F., Xiao, T., Song, W., Yisimayi, A., Huang, W., Li, Q., Wang, P., An, R., et al. (2021) · Nature · doi:10.1038/d41586-021-03796-6 · Cited by 227 · see citing works

Immunological imprinting of the antibody response in COVID-19 patients

Aydillo, T., Rombauts, A., Stadlbauer, D., Aslam, S., Abelenda-Alonso, G., Escalera, A., Amanat, F., Jiang, K., Krammer, F., Carratala, J., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-23977-1 · Cited by 223 · see citing works

In vivo monoclonal antibody efficacy against SARS-CoV-2 variant strains

Chen, R. E., Winkler, E. S., Case, J. B., Aziati, I. D., Bricker, T. L., Joshi, A., Darling, T. L., Ying, B., Errico, J. M., Shrihari, S., et al. (2021) · Nature · doi:10.1038/s41586-021-03720-y · Cited by 209 · see citing works

Live imaging of SARS-CoV-2 infection in mice reveals that neutralizing antibodies require Fc function for optimal efficacy

Ullah, I., Prévost, J., Ladinsky, M., Stone, H., Lu, M.-L., Anand, S., Beaudoin-Bussières, G., Symmes, K., Benlarbi, M., Ding, S.-L., et al. (2021) · Immunity · doi:10.1016/j.immuni.2021.08.015 · Cited by 152 · see citing works

The glycosylation in SARS-CoV-2 and its receptor ACE2

Gong, Y., Qin, S., Dai, L., & Tian, Z. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00809-8 · Cited by 207 · see citing works

Ultrapotent antibodies against diverse and highly transmissible SARS-CoV-2 variants

Wang, L., Zhou, T., Zhang, Y., Yang, E. S., Schramm, C. A., Shi, W., Pegu, A., Oloniniyi, O. K., Henry, A. R., Darko, S. W., et al. (2021) · Science · doi:10.1126/science.abh1766 · Cited by 191 · see citing works

Structural Characterization of SARS-CoV-2: Where We Are, and Where We Need to Be

Mariano, G., Farthing, R. J., Lale-Farjat, S. L. M., & Bergeron, J. R. C. (2020) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2020.605236 · Cited by 203 · see citing works

The humoral response and antibodies against SARS-CoV-2 infection

Qi, H., Liu, B., Wang, X.-Q., & Zhang, L.-Q. (2022) · Nature Immunology · doi:10.1038/s41590-022-01248-5 · Cited by 169 · see citing works

Structural basis for broad coronavirus neutralization

Sauer, M. M., Tortorici, M., Park, Y.-J., Walls, A., Homad, L. J., Acton, O., Bowen, J., Wang, C., Xiong, X., de van der Schueren, W. J., et al. (2020) · Nature Structural & Molecular Biology · doi:10.1038/s41594-021-00596-4 · Cited by 199 · see citing works

Elicitation of broadly protective sarbecovirus immunity by receptor-binding domain nanoparticle vaccines

Walls, A. C., Miranda, M. C., Schäfer, A., Pham, M. N., Greaney, A., Arunachalam, P. S., Navarro, M.-J., Tortorici, M. A., Rogers, K., O’Connor, M. A., et al. (2021) · Cell · doi:10.1016/j.cell.2021.09.015 · Cited by 185 · see citing works

Designed proteins assemble antibodies into modular nanocages

Divine, R., Dang, H. V., Ueda, G., Fallas, J. A., Vulovic, I., Sheffler, W., Saini, S., Zhao, Y. T., Raj, I. X., Morawski, P. A., et al. (2021) · Science · doi:10.1126/science.abd9994 · Cited by 184 · see citing works

Longitudinal analysis of humoral immunity against SARS-CoV-2 Spike in convalescent individuals up to 8 months post-symptom onset

Anand, S., Prévost, J., Nayrac, M., Beaudoin-Bussières, G., Benlarbi, M., Gasser, R., Brassard, N., Laumaea, A., Gong, S., Bourassa, C., et al. (2021) · bioRxiv · doi:10.1016/j.xcrm.2021.100290 · Cited by 177 · see citing works

Structural basis for potent antibody neutralization of SARS-CoV-2 variants including B.1.1.529

Zhou, T., Wang, L., Misasi, J., Pegu, A., Zhang, Y., Harris, D. R., Olia, A. S., Talana, C. A., Yang, E. S., Chen, M., et al. (2022) · Science · doi:10.1126/science.abn8897 · Cited by 160 · see citing works

ACE2-binding exposes the SARS-CoV-2 fusion peptide to broadly neutralizing coronavirus antibodies

Low, J. S., Jerak, J., Tortorici, M. A., McCallum, M., Pinto, D., Cassotta, A., Foglierini, M., Mele, F., Abdelnabi, R., Weynand, B., et al. (2022) · Science · doi:10.1126/science.abq2679 · Cited by 160 · see citing works

Inhalable Nanobody (PiN-21) prevents and treats SARS-CoV-2 infections in Syrian hamsters at ultra-low doses

Nambulli, S., Xiang, Y., Tilston-Lunel, N. L., Rennick, L., Sang, Z., Klimstra, W., Reed, D., Crossland, N., Shi, Y., & Duprex, W. P. (2021) · Science Advances · doi:10.1126/sciadv.abh0319 · Cited by 135 · see citing works

Immunity to SARS‐CoV‐2 induced by infection or vaccination

Dopico, X. C., Ols, S., Loré, K., & Hedestam, G. B. K. (2021) · Journal of Internal Medicine · doi:10.1111/joim.13372 · Cited by 164 · see citing works

Linear epitope landscape of the SARS-CoV-2 Spike protein constructed from 1,051 COVID-19 patients

Li, Y., Ma, M., Lei, Q., Wang, F., Hong, W., Lai, D., Hou, H., Xu, Z., Zhang, B., Chen, H., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.108915 · Cited by 163 · see citing works

An engineered decoy receptor for SARS-CoV-2 broadly binds protein S sequence variants

Chan, K. K., Tan, T. J. C., Narayanan, K. K., & Procko, E. (2021) · Science Advances · doi:10.1126/sciadv.abf1738 · Cited by 152 · see citing works

SARS-CoV-2 can recruit a heme metabolite to evade antibody immunity

Rosa, A., Pye, V. E., Graham, C., Muir, L., Seow, J., Ng, K., Cook, N., Rees-Spear, C., Parker, E., dos Santos, M. S., et al. (2021) · SciAdv · doi:10.1126/sciadv.abg7607 · Cited by 120 · see citing works

Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant

Graham, C., Seow, J., Huettner, I., Khan, H., Kouphou, N., Acors, S., Winstone, H., Pickering, S., Galão, R. P., Dupont, L., et al. (2021) · Immunity · doi:10.1016/j.immuni.2021.03.023 · Cited by 130 · see citing works

Effect of SARS-CoV-2 B.1.1.7 mutations on spike protein structure and function

Yang, T., Yu, P., Chang, Y., Liang, K.-H., Tso, H.-C., Ho, M., Wy, C., Lin, H.-T., Wu, H., & Hsu, S. D. (2021) · Nature Structural & Molecular Biology · doi:10.1038/s41594-021-00652-z · Cited by 159 · see citing works

Antibody-mediated neutralization of SARS-CoV-2

Gruell, H., Vanshylla, K., Weber, T., Barnes, C. O., Kreer, C., & Klein, F. (2022) · Immunity · doi:10.1016/j.immuni.2022.05.005 · Cited by 145 · see citing works

Analysis of memory B cells identifies conserved neutralizing epitopes on the N-terminal domain of variant SARS-Cov-2 spike proteins

Wang, Z., Muecksch, F., Cho, A., Gaebler, C., Hoffmann, H.-H., Ramos, V., Zong, S., Cipolla, M., Johnson, B., Schmidt, F., et al. (2022) · Immunity · doi:10.1016/j.immuni.2022.04.003 · Cited by 142 · see citing works

Nanobody cocktails potently neutralize SARS-CoV-2 D614G N501Y variant and protect mice

Pymm, P., Adair, A., Chan, L., Cooney, J. P., Mordant, F., Allison, C., Lopez, E., Haycroft, E., O, Neill, M., et al. (2021) · Proceedings of the National Academy of Sciences of the United States of America · doi:10.1073/pnas.2101918118 · Cited by 134 · see citing works

A single intranasal dose of chimpanzee adenovirus-vectored vaccine protects against SARS-CoV-2 infection in rhesus macaques

Hassan, A. O., Feldmann, F., Zhao, H.-Y., Curiel, D., Okumura, A., Tang-Huau, T.-L., Case, J., Meade-White, K., Callison, J. A., Chen, R. E., et al. (2021) · Cell Reports Medicine · doi:10.1016/j.xcrm.2021.100230 · Cited by 85 · see citing works

SARS-CoV-2 Neutralizing Antibodies for COVID-19 Prevention and Treatment

Li, D., Sempowski, G. D., Saunders, K. O., Acharya, P., & Haynes, B. F. (2021) · Annual Review of Medicine · doi:10.1146/annurev-med-042420-113838 · Cited by 132 · see citing works

Scientific rationale for developing potent RBD-based vaccines targeting COVID-19

Kleanthous, H., Silverman, J., Makar, K., Yoon, I., Jackson, N. A. C., & Vaughn, D. (2021) · npj Vaccines · doi:10.1038/s41541-021-00393-6 · Cited by 137 · see citing works

Antibody-mediated broad sarbecovirus neutralization through ACE2 molecular mimicry

Park, Y., Marco, A. D., Starr, T. N., Liu, Z., Pinto, D., Walls, A. C., Zatta, F., Zepeda, S. K., Bowen, J. E., Sprouse, K. R., et al. (2022) · Science · doi:10.1126/science.abm8143 · Cited by 132 · see citing works

Molecular characteristics, immune evasion, and impact of SARS-CoV-2 variants

Sun, C., Xie, C., Bu, G., Zhong, L., & Zeng, M. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01039-2 · Cited by 139 · see citing works

N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2

McCallum, M., Marco, A. D., Lempp, F., Tortorici, M. A., Pinto, D., Walls, A. C., Beltramello, M., Chen, A., Liu, Z., Zatta, F., et al. (2021) · doi:10.1101/2021.01.14.426475 · Cited by 901 · see citing works

Antibody and B cell responses to SARS-CoV-2 infection and vaccination

Röltgen, K., & Boyd, S. (2021) · Cell Host and Microbe · doi:10.1016/j.chom.2021.06.009 · Cited by 123 · see citing works

Structural basis and mode of action for two broadly neutralizing antibodies against SARS-CoV-2 emerging variants of concern

Li, W., Chen, Y., Prévost, J., Ullah, I., Lu, M., Gong, S. Y., Tauzin, A., Gasser, R., Vézina, D., Anand, S. P., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.110210 · Cited by 125 · see citing works

Fab and Fc contribute to maximal protection against SARS-CoV-2 following NVX-CoV2373 subunit vaccine with Matrix-M vaccination

Gorman, M. J., Patel, N., Guebre‐Xabier, M., Zhu, A. L., Atyeo, C. G., Pullen, K. M., Loos, C., Goez-Gazi, Y., Carrion, R., Tian, J.-H., et al. (2021) · Cell Reports Medicine · doi:10.1016/j.xcrm.2021.100405 · Cited by 121 · see citing works

Structure genomics of SARS-CoV-2 and its Omicron variant: drug design templates for COVID-19

Wu, C., Yin, W., Jiang, Y., & Xu, H. E. (2022) · Acta Pharmacologica Sinica · doi:10.1038/s41401-021-00851-w · Cited by 127 · see citing works

SARS-CoV-2 immune evasion by variant B.1.427/B.1.429Preprint

McCallum, M., Bassi, J., Marco, A. D., Chen, A., Walls, A. C., di Iulio, J., Tortorici, M. A., Navarro, M.-J., Silacci-Fregni, C., Saliba, C., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.03.31.437925 · Cited by 128 · see citing works

An intranasal vaccine durably protects against SARS-CoV-2 variants in mice

Hassan, A. O., Shrihari, S., Gorman, M. J., Ying, B., Yuan, D., Raju, S., Chen, R. E., Dmitriev, I. P., Kashentseva, E. A., Adams, L. J., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109452 · Cited by 129 · see citing works

An adjuvant strategy enabled by modulation of the physical properties of microbial ligands expands antigen immunogenicity

Borriello, F., Poli, V., Shrock, E. L., Spreafico, R., Liu, X., Pishesha, N., Carpenet, C., Chou, J., di Gioia, M., McGrath, M., et al. (2022) · Cell · doi:10.1016/j.cell.2022.01.009 · Cited by 100 · see citing works

Bispecific antibodies targeting distinct regions of the spike protein potently neutralize SARS-CoV-2 variants of concern

Cho, H., Gonzales-Wartz, K. K., Huang, D.-L., Yuan, M., Peterson, M., Liang, J. Y., Beutler, N., Torres, J., Cong, Y., Postnikova, E., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abj5413 · Cited by 109 · see citing works

A serum-stable RNA aptamer specific for SARS-CoV-2 neutralizes viral entry

Valero, J., Civit, L., Dupont, D. M., Selnihhin, D., Reinert, L. S., Idorn, M., Israels, B. A., Bednarz, A., Bus, C., Asbach, B., et al. (2021) · Proceedings of the National Academy of Sciences of the United States of America · doi:10.1073/pnas.2112942118 · Cited by 99 · see citing works

A Fc-enhanced NTD-binding non-neutralizing antibody delays virus spread and synergizes with a nAb to protect mice from lethal SARS-CoV-2 infection

Beaudoin-Bussières, G., Chen, Y., Ullah, I., Prévost, J., Tolbert, W. D., Symmes, K., Ding, S., Benlarbi, M., Gong, S. Y., Tauzin, A., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110368 · Cited by 120 · see citing works

Persistent immune imprinting occurs after vaccination with the COVID-19 XBB.1.5 mRNA booster in humans

Tortorici, M. A., Addetia, A., Seo, A. J., Brown, J. T., Sprouse, K., Logue, J., Clark, E., Franko, N., Chu, H. Y., & Veesler, D. (2024) · Immunity · doi:10.1016/j.immuni.2024.02.016 · Cited by 124 · see citing works

Broad cross-reactivity across sarbecoviruses exhibited by a subset of COVID-19 donor-derived neutralizing antibodies

Jette, C. A., Cohen, A. A., Gnanapragasam, P. N. P., Muecksch, F., Lee, Y. E., Huey‐Tubman, K. E., Schmidt, F., Hatziioannou, T., Bieniasz, P. D., Nussenzweig, M. C., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109760 · Cited by 116 · see citing works

Humoral immune responses and neutralizing antibodies against SARS-CoV-2; implications in pathogenesis and protective immunity

Carrillo, J., Izquierdo‐Useros, N., Ávila‐Nieto, C., Pradenas, E., Clotet, B., & Blanco, J. (2020) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2020.10.108 · Cited by 114 · see citing works

Prediction and mitigation of mutation threats to COVID-19 vaccines and antibody therapies

Chen, J., Gao, K., Wang, R., & Wei, G. (2021) · Chemical Science · doi:10.1039/d1sc01203g · Cited by 112 · see citing works

Engineering of the current nucleoside-modified mRNA-LNP vaccines against SARS-CoV-2

Granados-Riveron, J. T., & Aquino‐Jarquín, G. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111953 · Cited by 115 · see citing works

A large-scale systematic survey reveals recurring molecular features of public antibody responses to SARS-CoV-2

Wang, Y., Yuan, M., Lv, H., Peng, J., Wilson, I. A., & Wu, N. C. (2022) · Immunity · doi:10.1016/j.immuni.2022.03.019 · Cited by 114 · see citing works

Cryo-EM structure of the SARS-CoV-2 Omicron spike

Cerutti, G., Guo, Y., Liu, L., Liu, L., Zhang, Z., Luo, Y., Huang, Y., Wang, H. H., Ho, D. D., Sheng, Z., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110428 · Cited by 104 · see citing works

Isolation and characterization of cross-neutralizing coronavirus antibodies from COVID-19+ subjects

Jennewein, M. F., MacCamy, A. J., Akins, N. R., Feng, J., Homad, L. J., Hurlburt, N., Seydoux, E., Wan, Y.-H., Stuart, A., Edara, V., et al. (2021) · bioRxiv · doi:10.1016/j.celrep.2021.109353 · Cited by 128 · see citing works

Discovery and Characterization of Spike N‐Terminal Domain‐Binding Aptamers for Rapid SARS‐CoV‐2 Detection

Kacherovsky, N. A., Yang, L. F., Dang, H. V., Cheng, E. L., Cardle, I. I., Walls, A. C., McCallum, M., Sellers, D. L., DiMaio, F., Salipante, S. J., et al. (2021) · Angewandte Chemie International Edition · doi:10.1002/anie.202107730 · Cited by 106 · see citing works

Convergent antibody responses to the SARS-CoV-2 spike protein in convalescent and vaccinated individuals

Chen, E. C., Gilchuk, P., Zost, S. J., Suryadevara, N., Winkler, E. S., Cabel, C. R., Binshtein, E., Chen, R. E., Sutton, R. E., Rodriguez, J. L., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109604 · Cited by 76 · see citing works

Markers of Polyfunctional SARS-CoV-2 Antibodies in Convalescent Plasma

Natarajan, H., Crowley, A. R., Butler, S. E., Xu, S., Weiner, J. A., Bloch, E. M., Littlefield, K. E., Wieland‐Alter, W., Connor, R. I., Wright, P. F., et al. (2021) · mBio · doi:10.1128/mbio.00765-21 · Cited by 98 · see citing works

Possible Link between Higher Transmissibility of Alpha, Kappa and Delta Variants of SARS-CoV-2 and Increased Structural Stability of Its Spike Protein and hACE2 Affinity

Kumar, V., Singh, J., Hasnain, S. E., & Sundar, D. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22179131 · Cited by 94 · see citing works

A potently neutralizing SARS-CoV-2 antibody inhibits variants of concern by utilizing unique binding residues in a highly conserved epitope

VanBlargan, L. A., Adams, L., Liu, Z.-M., Chen, R. E., Gilchuk, P., Raju, S., Smith, B. K., Zhao, H.-Y., Case, J., Winkler, E. S., et al. (2021) · Immunity · doi:10.1016/j.immuni.2021.08.016 · Cited by 95 · see citing works

Structural analysis of receptor binding domain mutations in SARS-CoV-2 variants of concern that modulate ACE2 and antibody binding

Mannar, D., Saville, J. W., Zhu, X. Q., Srivastava, S. S., Berezuk, A., Zhou, S., Tuttle, K. S., Kim, A., Li, W., Dimitrov, D. S., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.110156 · Cited by 88 · see citing works

Structural and biochemical rationale for enhanced spike protein fitness in delta and kappa SARS-CoV-2 variants

Saville, J. W., Mannar, D., Zhu, X. Q., Srivastava, S. S., Berezuk, A., Demers, J., Zhou, S., Tuttle, K. S., Sekirov, I., Kim, A., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-28324-6 · Cited by 93 · see citing works

Conformational dynamics and allosteric modulation of the SARS-CoV-2 spike

Díaz-Salinas, M. A., Li, Q., Ejemel, M., Yurkovetskiy, L., Luban, J., Shen, K., Wang, Y., & Munro, J. B. (2022) · eLife · doi:10.7554/elife.75433 · Cited by 93 · see citing works

Structure, receptor recognition, and antigenicity of the human coronavirus CCoV-HuPn-2018 spike glycoprotein

Tortorici, M. A., Walls, A. C., Joshi, A., Park, Y., Eguia, R. T., Miranda, M. C., Kepl, E., Dosey, A. M., Stevens‐Ayers, T., Boeckh, M. J., et al. (2022) · Cell · doi:10.1016/j.cell.2022.05.019 · Cited by 87 · see citing works

B cell genomics behind cross-neutralization of SARS-CoV-2 variants and SARS-CoV

Scheid, J. F., Barnes, C. O., Eraslan, B., Hudak, A., Keeffe, J. R., Cosimi, L. A., Brown, E., Muecksch, F., Weisblum, Y., Zhang, S., et al. (2021) · Cell · doi:10.1016/j.cell.2021.04.032 · Cited by 90 · see citing works

SARS-CoV-2 vaccines in advanced clinical trials: Where do we stand?

Chakraborty, S., Mallajosyula, V. V. A., Tato, C. M., Tan, G. S., & Wang, T. T. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.01.014 · Cited by 87 · see citing works

Similarities and Dissimilarities of COVID-19 and Other Coronavirus Diseases

Fung, T. S., & Liu, D. X. (2021) · Annual Review of Microbiology · doi:10.1146/annurev-micro-110520-023212 · Cited by 85 · see citing works

A strong cocktail against SARS-CoV-2

Vinson, V. J. (2020) · Science · doi:10.1126/science.370.6519.926-g

Human monoclonal antibodies block the binding of SARS-CoV-2 spike protein to angiotensin converting enzyme 2 receptor

Chen, X., Li, R., Pan, Z., Qian, C., Yang, Y., You, R., Zhao, J., Liu, P., Gao, L., Li, Z., et al. (2020) · Cellular and Molecular Immunology · doi:10.1038/s41423-020-0426-7 · Cited by 325 · see citing works

Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail

Hansen, J., Baum, A., Pascal, K. E., Russo, V., Giordano, S., Wloga, E., Fulton, B. O., Yan, Y., Koon, K., Patel, K., et al. (2020) · Science · doi:10.1126/science.abd0827 · Cited by 1,210 · see citing works

Pan-sarbecovirus prophylaxis with human anti-ACE2 monoclonal antibodies

Zhang, F., Jenkins, J., de Carvalho, R. A., Nakandakari-Higa, S., Chen, T., Abernathy, M. E., Baharani, V. A., Nyakatura, E. K., Andrew, D. P., Lebedeva, I. V., et al. (2023) · Nature Microbiology · doi:10.1038/s41564-023-01389-9 · Cited by 18 · see citing works

A broadly neutralizing humanized ACE2-targeting antibody against SARS-CoV-2 variants

Du, Y., Shi, R., Zhang, Y., Duan, X., Li, L., Zhang, J., Wang, F., Zhang, R., Shen, H., Wang, Y., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-25331-x · Cited by 61 · see citing works